Exploratory Study of Early Biomarkers Allowing Dynamic Assessment of Response to Treatment in Cancers of the Head and Neck

Launched by ROYAL MARSDEN NHS FOUNDATION TRUST · Dec 6, 2022

Keywords

ClinConnect Summary

This clinical trial, called DART, is looking at how certain biological markers in the body can help doctors understand how well treatment is working for patients with head and neck cancer, specifically a type called squamous cell carcinoma. The study aims to find early signs that show whether the treatment, particularly immunotherapy, is effective. This could help doctors make better decisions about patient care.

To participate in this trial, you need to be at least 18 years old and have been diagnosed with head and neck cancer that has either returned after treatment or is advanced and cannot be cured. You also need to be receiving immunotherapy and be able to give consent for providing samples of your biological material, like blood. Participants will undergo regular sample collection throughout the study, but those who cannot do this or are pregnant cannot take part. This trial is currently recruiting participants, and it offers a chance to contribute to important research that may improve future treatments for head and neck cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years or older
• • Patients with histologically confirmed cancer of the head and neck with evidence of recurrent or locally advanced cancer not suitable for treatment with curative intent, or metastatic disease.
• • Receiving immunotherapy
• • Ability to give informed consent for biological sample collection.
• Exclusion Criteria:
• • Unable to undergo serial sample collection
• • Pregnancy